In a warning letter to Natural Native LLC, the FDA noted: The FDA also focused on companies that market CBD to vulnerable populations, including infants and children. FDA is Concerned about Companies that Market CBD to Vulnerable Populations In these recent warning letters, the FDA also flagged claims to treat other serious conditions, including: HIV/AIDS, ADHD, Crohn’s disease, opioid addiction, autism spectrum disorders, diabetes, schizophrenia, and multiple sclerosis.
#G2 RED PILL PLUS#
In fact, 12 of the 15 warning letters cited claims to treat cancer.įor example: Whole Leaf Organics claimed that one of its CBD products “attacks cancer cells and help those struggling with advanced stage cancers.” Red Pill Medical claimed: “There are numerous anecdotal accounts of CBD doing great things including curing cancer, stopping seizures, chronic pain, treating obesity…the list goes on and on.” Koi CBD claimed that: “Not only does the research show that CBD benefits including being effective in fighting breast cancer cells, data also suggest that it can be used to inhibit the invasion of lung and colon cancer, plus it possesses anti-tumor properties in gliomas and has been used to treat leukemia.” It is clear that the FDA is continuing to focus on companies that make claims to treat serious diseases. Is the FDA foreshadowing expanded enforcement? Or merely reprimanding a handful of brands that are making egregious claims? Let’s take a deeper dive into the FDA’s latest batch of warning letters. The agency updated its consumer advisory on CBD to warn of possible negative side effects and issued 15 warning letters to CBD companies – which is more CBD-related warning letters than the FDA has issued in the past three years. Last week, the FDA took off the gloves in its fight against illicit CBD products.
0 kommentar(er)
